Lv1
90 积分 2025-08-15 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
8天前
已完结
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo
1个月前
已完结
Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach
2个月前
已完结
Optimal two-stage designs for phase II clinical trials
6个月前
已完结
追踪国外六大监管机构获批药品在中国的可及性
6个月前
已关闭
论药品监管指导原则的法律渊源与法律运用
6个月前
已完结
小分子药物研发中代谢产物非临床研究的关注要点
7个月前
已完结
An FDA oncology analysis of antibody-drug conjugates
7个月前
已完结
皖公网安备34019202002308
